The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for ...

Few areas of healthcare are as sensitive as cancer treatment. Each year, around 44,000 cancer tumours are diagnosed here.

A recent study by the University of Turku and the University of Helsinki in Finland and the Finnish Social Insurance Institution Kela reveals that the average duration of ADHD medication for children ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...